While epidemiological studies associate elevated serum PRL levels with increased ER+ breast cancer risk26, gene expression analyses reveal PRLR presence across ER+, HER2+, and triple-negative tumors, challenging this paradigm. The gene discussed is ERBB2; the disease is breast carcinoma.